|
1
|
Ueno H, Klechevsky E, Morita R, et al:
Dendritic cell subsets in health and disease. Immunol Rev.
219:118–142. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Palucka K, Ueno H, Roberts L, Fay J and
Banchereau J: Dendritic cell subsets as vectors and targets for
improved cancer therapy. Curr Top Microbiol Immunol. 344:173–192.
2012.PubMed/NCBI
|
|
3
|
Gilboa E: DC-based cancer vaccines. J Clin
Invest. 117:1195–1203. 2007. View
Article : Google Scholar
|
|
4
|
Pajtasz-Piasecka E and Indrova M:
Dendritic cell-based vaccines for the therapy of experimental
tumors. Immunotherapy. 2:257–268. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Palucka K, Ueno H and Banchereau J: Recent
developments in cancer vaccines. J Immunol. 186:1325–1331. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rossowska J, Pajtasz-Piasecka E, Szyda A,
Krawczenko A, Zietara N and Dus D: Tumour antigen-loaded mouse
dendritic cells maturing in the presence of inflammatory cytokines
are potent activators of immune response in vitro but not
in vivo. Oncol Rep. 21:1539–1549. 2009.PubMed/NCBI
|
|
7
|
Vegh Z and Mazumder A: Generation of tumor
cell lysate-loaded dendritic cells preprogrammed for IL-12
production and augmented T cell response. Cancer Immunol
Immunother. 52:67–79. 2003.PubMed/NCBI
|
|
8
|
Tatsumi T, Takehara T, Kanto T, et al:
Administration of interleukin-12 enhances the therapeutic efficacy
of dendritic cell-based tumor vaccines in mouse hepatocellular
carcinoma. Cancer Res. 61:7563–7567. 2001.PubMed/NCBI
|
|
9
|
Fallarino F, Uyttenhove C, Boon T and
Gajewski TF: Improved efficacy of dendritic cell vaccines and
successful immunization with tumor antigen peptide-pulsed
peripheral blood mononuclear cells by coadministration of
recombinant murine interleukin-12. Int J Cancer. 80:324–333. 1999.
View Article : Google Scholar
|
|
10
|
Gately MK, Warrier RR, Honasoge S, et al:
Administration of recombinant IL-12 to normal mice enhances
cytolytic lymphocyte activity and induces production of IFN-gamma
in vivo. Int Immunol. 6:157–167. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
McKnight AJ, Zimmer GJ, Fogelman I, Wolf
SF and Abbas AK: Effects of IL-12 on helper T cell-dependent immune
responses in vivo. J Immunol. 152:2172–2179. 1994.PubMed/NCBI
|
|
12
|
Brunda MJ, Luistro L, Rumennik L, et al:
Antitumor activity of interleukin 12 in preclinical models. Cancer
Chemother Pharmacol. 38(Suppl): S16–S21. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nastala CL, Edington HD, McKinney TG, et
al: Recombinant IL-12 administration induces tumor regression in
association with IFN-gamma production. J Immunol. 153:1697–1706.
1994.PubMed/NCBI
|
|
14
|
Pajtasz-Piasecka E, Rossowska J, Szyda A,
Krawczenko A and Dus D: Generation of anti-tumor response by JAWS
II mouse dendritic cells transduced with murine interleukin 12
genes. Oncol Rep. 17:1249–1257. 2007.PubMed/NCBI
|
|
15
|
Xu Y, Darcy PK and Kershaw MH:
Tumor-specific dendritic cells generated by genetic redirection of
Toll-like receptor signaling against the tumor-associated antigen,
erbB2. Cancer Gene Ther. 14:773–780. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zapala L, Drela N, Bil J, Nowis D, Basak
GW and Lasek W: Optimization of activation requirements of immature
mouse dendritic JAWSII cells for in vivo application. Oncol
Rep. 25:831–840. 2011.PubMed/NCBI
|
|
17
|
Basak GW, Zapala L, Wysocki PJ, Mackiewicz
A, Jakobisiak M and Lasek W: Interleukin 15 augments antitumor
activity of cytokine gene-modified melanoma cell vaccines in a
murine model. Oncol Rep. 19:1173–1179. 2008.PubMed/NCBI
|
|
18
|
Switaj T, Jalili A, Jakubowska AB, et al:
CpG immunostimulatory oligodeoxynucleotide 1826 enhances antitumor
effect of interleukin 12 gene-modified tumor vaccine in a melanoma
model in mice. Clin Cancer Res. 10:4165–4175. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ballestrero A, Boy D, Moran E, Cirmena G,
Brossart P and Nencioni A: Immunotherapy with dendritic cells for
cancer. Adv Drug Deliv Rev. 60:173–183. 2008. View Article : Google Scholar
|
|
20
|
Palucka K and Banchereau J: Cancer
immunotherapy via dendritic cells. Nat Rev Cancer. 12:265–277.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Haase C, Michelsen BK and Jorgensen TN:
CD40 is necessary for activation of naive T cells by a dendritic
cell line in vivo but not in vitro. Scand J Immunol. 59:237–245.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jorgensen TN, Haase C and Michelsen BK:
Treatment of an immortalized APC cell line with both cytokines and
LPS ensures effective T-cell activation in vitro. Scand J Immunol.
56:492–503. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Peterson AC, Harlin H and Gajewski TF:
Immunization with Melan-A peptide-pulsed peripheral blood
mononuclear cells plus recombinant human interleukin-12 induces
clinical activity and T-cell responses in advanced melanoma. J Clin
Oncol. 21:2342–2348. 2003. View Article : Google Scholar
|
|
24
|
Wehner R, Dietze K, Bachmann M and Schmitz
M: The bidirectional crosstalk between human dendritic cells and
natural killer cells. J Innate Immun. 3:258–263. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Manetti R, Parronchi P, Giudizi MG, et al:
Natural killer cell stimulatory factor [interleukin 12 (IL-12)]
induces T helper type 1 (Th1)-specific immune responses and
inhibits the development of IL-4-producing Th cells. J Exp Med.
177:1199–1204. 1993.
|
|
26
|
Bielawska-Pohl A, Blesson S, Benlalam H,
et al: The anti-angiogenic activity of IL-12 is increased in
iNOS−/− mice and involves NK cells. J Mol Med.
88:775–784. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Airoldi I, Di Carlo E, Cocco C, et al:
Endogenous IL-12 triggers an antiangiogenic program in melanoma
cells. Proc Natl Acad Sci USA. 104:3996–4001. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hill HC, Conway TF Jr, Sabel MS, et al:
Cancer immunotherapy with interleukin 12 and granulocyte-macrophage
colony-stimulating factor-encapsulated microspheres: coinduction of
innate and adaptive antitumor immunity and cure of disseminated
disease. Cancer Res. 62:7254–7263. 2002.
|
|
29
|
Kozar K, Kaminski R, Switaj T, et al:
Interleukin 12-based immunotherapy improves the antitumor
effectiveness of a low-dose 5-Aza-2′-deoxycitidine treatment in
L1210 leukemia and B16F10 melanoma models in mice. Clin Cancer Res.
9:3124–3133. 2003.PubMed/NCBI
|
|
30
|
Grohmann U, Bianchi R, Ayroldi E, et al: A
tumor-associated and self antigen peptide presented by dendritic
cells may induce T cell anergy in vivo, but IL-12 can prevent or
revert the anergic state. J Immunol. 158:3593–3602. 1997.PubMed/NCBI
|
|
31
|
Kelleher P and Knight SC: IL-12 increases
CD80 expression and the stimulatory capacity of bone marrow-derived
dendritic cells. Int Immunol. 10:749–755. 1998. View Article : Google Scholar : PubMed/NCBI
|
